Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

The purpose of the first phase of the study is to determine whether, and at what dose, depsipeptide, bortezomib and dexamethasone can be safely administered to patients with Multiple Myeloma. The second phase of the study will establish whether depsipeptide, bortezomib and dexamethasone is effective in the treatment of patients …

plasmacytoma
neutrophil count
growth factor
monoclonal antibodies
calcium
  • 31 views
  • 07 Nov, 2020
  • 1 location
Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

This study evaluates the efficacy of Oral azacitidine versus single-agent Investigator's Choice Therapy in patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma.

  • 47 views
  • 24 Jan, 2021
  • 39 locations
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is

hodgkin's disease
t-cell lymphoma
multiple myeloma
cancer
lymphoma
  • 11 views
  • 24 Jan, 2021
  • 2 locations
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

This phase I/II trial studies the side effects of pembrolizumab and romidepsin and to see how well they work in treating participants with peripheral T-cell lymphoma that has come back or that

  • 47 views
  • 27 Jan, 2021
  • 2 locations
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lymphoma (PTCL) who

hysterectomy
neutrophil count
hdac inhibitor
revlimid
cancer
  • 131 views
  • 24 Jan, 2021
  • 5 locations
A Phase 1 Study of Romidepsin CC-486 (5-azacitidine) Dexamethasone and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

inhibitors (HDACi) such as romidepsin show modest clinical activity with single agent the overall response (ORR) around 25% Combination of romidepsin and 5-azacitidine (hypomethylating agents) was

  • 0 views
  • 13 Feb, 2021
  • 1 location
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

This is a Phase I Trial to assess the feasibility of Romidepsin combined with Brentuximab Vedotin for patients requiring Systemic Therapy for Cutaneous T-cell Lymphoma.

systemic therapy
cutaneous t-cell lymphoma
mycosis fungoides
flow cytometry
neutrophil count
  • 0 views
  • 28 Jan, 2021
  • 1 location
Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.

A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced

pancreatic ductal adenocarcinoma
lenalidomide
azacitidine
cancer chemotherapy
paclitaxel
  • 0 views
  • 26 Jan, 2021
  • 9 locations
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.

t-cell lymphoma
measurable disease
chidamide
peripheral t-cell lymphoma
  • 0 views
  • 25 Jan, 2021
  • 1 location
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

This research is being done to study the safety of implanting and retrieving a microdevice that releases up to 19 drugs directly within a cancerous lesion as a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma and peripheral T cell lymphoma

systemic therapy
phototherapy
corticosteroids
neutrophil count
monoclonal antibodies
  • 0 views
  • 25 Jan, 2021